Pentostatin and Rituximab Therapy for Previously Untreated B-CLL

We have shown that the combination of pentostatin (P), cyclophosphamide (C) and rituximab (R) achieves an overall response (OR) rate >90% with more than 40% complete responses (CR) in patients with untreated CLL. To evaluate if the tolerability of this regimen could be enhanced without sacrificin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kay, Neil E., Wu, Wenting, Kabat, Brian, LaPlant, Betsy, Lin, Thomas S., Byrd, John C., Jelinek, Diane F., Grever, Michael R., Zent, Clive S., Call, Timothy G., Shanafelt, Tait D.
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2919331/
https://ncbi.nlm.nih.gov/pubmed/20187101
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25028
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars